Hims & Hers Health, Inc. (NYSE:HIMS) Stock Has Consensus Target Price of $32.43 According to Analysts

Posted by Brian Himes on Oct 27th, 2026

Shares of Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) have earned an average recommendation of “Hold” from the fifteen brokerages that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and three have given a buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $32.43.

Several equities research analysts recently weighed in on the stock. Canaccord Genuity Group increased their target price on shares of Hims & Hers Health from $32.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, July 1st. Morgan Stanley upped their price target on Hims & Hers Health from $21.00 to $28.00 and gave the company an “equal weight” rating in a report on Tuesday, August 11th. Wall Street Zen upgraded Hims & Hers Health from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. JPMorgan Chase & Co. began coverage on Hims & Hers Health in a research report on Friday, September 11th. They issued a “neutral” rating and a $32.00 price objective for the company. Finally, Truist Financial lifted their price objective on Hims & Hers Health from $27.00 to $32.00 and gave the stock a “hold” rating in a report on Monday, August 24th.

Get Our Latest Analysis on HIMS

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

Positive Sentiment: Hims & Hers is seeking dismissal of a data-privacy case brought by the Federal Trade Commission and several states. A successful dismissal could reduce potential financial penalties, litigation costs, and reputational damage, although the case remains unresolved. Hims & Hers Seeks Dismissal of FTC, States’ Data Privacy Case
Neutral Sentiment: Multiple law firms announced that investors who purchased HIMS securities between August 4, 2025, and July 29, 2026, have until November 2, 2026, to seek lead-plaintiff status in a securities-fraud class action. The announcements are largely duplicative legal notices, but they highlight growing investor scrutiny. HIMS Securities Fraud Class Action Deadline Alert
Negative Sentiment: The securities litigation alleges that Hims & Hers and certain executives failed to disclose material adverse information, including allegedly deceptive or unlawful privacy practices referenced in the FTC’s complaint. If the claims advance, the company could face legal expenses, settlement costs, damages, and additional reputational harm. HIMS Securities Class Action Deadline
Negative Sentiment: The concentration of class-action reminders from several firms reinforces concerns about regulatory compliance and management disclosures. These developments add uncertainty to HIMS’s outlook beyond its operating results and may weigh on valuation until the FTC and shareholder cases become clearer. Kaplan Fox HIMS Investor Class Action Notice

Hims & Hers Health Trading Down 0.4%

Hims & Hers Health stock opened at $27.59 on Thursday. Hims & Hers Health has a 52 week low of $13.74 and a 52 week high of $50.19. The company has a debt-to-equity ratio of 4.21, a quick ratio of 0.87 and a current ratio of 0.93. The firm has a market capitalization of $6.44 billion, a PE ratio of -43.79 and a beta of 2.44. The business’s 50-day simple moving average is $29.12 and its 200-day simple moving average is $27.18.

Hims & Hers Health (NYSE:HIMS – Get Free Report) last announced its earnings results on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.32). Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The business had revenue of $753.21 million for the quarter, compared to the consensus estimate of $698.90 million. During the same quarter in the previous year, the company earned $0.17 EPS. Hims & Hers Health’s revenue for the quarter was up 38.2% compared to the same quarter last year. Equities research analysts forecast that Hims & Hers Health will post -0.16 earnings per share for the current year.

Insider Buying and Selling

In other news, COO Michael Chi sold 14,027 shares of the business’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $28.39, for a total value of $398,226.53. Following the sale, the chief operating officer owned 456,660 shares in the company, valued at approximately $12,964,577.40. The trade was a 2.98% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Soleil Boughton sold 25,111 shares of the company’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $27.55, for a total transaction of $691,808.05. Following the completion of the sale, the insider directly owned 313,964 shares in the company, valued at approximately $8,649,708.20. The trade was a 7.41% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 130,443 shares of company stock valued at $3,731,426. 11.76% of the stock is owned by insiders.

Hedge Funds Weigh In On Hims & Hers Health

Institutional investors have recently added to or reduced their stakes in the company. Bank of America Corp DE increased its holdings in shares of Hims & Hers Health by 194.4% during the first quarter. Bank of America Corp DE now owns 4,357,672 shares of the company’s stock worth $90,465,000 after buying an additional 2,877,550 shares in the last quarter. State of Michigan Retirement System raised its position in Hims & Hers Health by 13.7% in the 1st quarter. State of Michigan Retirement System now owns 2,338,600 shares of the company’s stock valued at $48,549,000 after purchasing an additional 280,900 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in Hims & Hers Health in the second quarter worth $46,220,000. Principal Financial Group Inc. boosted its stake in Hims & Hers Health by 97.3% in the first quarter. Principal Financial Group Inc. now owns 1,282,266 shares of the company’s stock worth $26,620,000 after purchasing an additional 632,282 shares in the last quarter. Finally, Bienville Capital Management LLC acquired a new position in Hims & Hers Health in the second quarter worth $27,242,000. 63.52% of the stock is owned by institutional investors.

Hims & Hers Health Company Profile

(Get Free Report)

Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides telehealth services through the Hims and Hers platforms. The company connects consumers with licensed healthcare providers through online consultations and offers access to prescription and over-the-counter products, as well as educational and wellness resources.

Its services address areas including sexual health, hair loss, skincare, mental health, weight management and primary care. Depending on the condition and eligibility requirements, customers may receive personalized treatment plans and have prescribed medications delivered directly to them.